Search - tctmd.com

Displaying 61 - 80 of 125

Sort: Relevancy | Date

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

July 25, 2022

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

June 21, 2022

TCTMD’s Top 10 Most Popular Stories for May 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2022

June 01, 2022

Dapagliflozin Boosts Health Status Across LVEF Range

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

May 23, 2022

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

May 05, 2022

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

May 03, 2022

FDA Approves Empagliflozin for Treatment of HFpEF

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

News Daily News

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

January 21, 2022

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

January 10, 2022

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

TCTMD’s Top 10 Most Popular Stories for September 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

October 01, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

News Conference News ESC 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

August 28, 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

FDA Green-lights Empagliflozin for HF With Reduced Ejection Fraction

News Daily News

FDA Green-lights Empagliflozin for HF With Reduced Ejection Fraction

Michael O'Riordan

August 19, 2021

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

July 06, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.